An Antihyperlipidemic Agents Review for Atherosclerosis Treatment

Authors

  • Rutuja Talekar Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India
  • Nanasaheb Gorade Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India
  • Sachin Jadhav Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India
  • Pratiksha Chormage Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India
  • Shivani Gadekar Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India
  • Swati H.Tarkase Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India
  • Dr.Gajanan Sanap Department of Medicinal Chemistry, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri.Phulambri, Chh. Sambhajinagar. 431111, India

DOI:

https://doi.org/10.22270/ajprd.v14i2.1734

Abstract

Elevated levels of one or more plasma lipids, including triglycerides, cholesterol, cholesterol esters, phospholipids, and/or plasma lipoproteins, including very low-density lipoprotein and decreased levels of high-density lipoprotein are indicative of a medical condition called hyperlipidemia. This elevation in plasma lipids is one of the primary risk factors for cardiovascular diseases.Statins and fibrates remain the main antihyperlipidemic drugs for the treatment of elevated plasma cholesterol and triglycerides, respectively, at the cost of major negative effects on the liver and muscles. Hyperlipidemia is the main risk factor for coronary heart disease.

 

Downloads

Download data is not yet available.

References

Asija R, Singh C. A Comprehensive Review on Antihyperlipidemic Activity of Various Medicinal Plants. Available online on www.ijcpr.com International Journal of Current Pharmaceutical Review and Research 2016.

Ritter J, Lewis L, Mant T, Ferro A. Hyperlipidemias. In: A Textbook of Clinical Pharmacology and Therapeutics, 5Ed. 2020. p. 398–413. doi:10.1201/b13234-52

Kalita S, Hazarika A. A Mini-review on Plants with Potential Anti-hyperlipidemic Properties of Northeast India. International Research Journal of Plant Science. 2021;12(3):1–11. doi:10.14303/irjps.2021.15

Sharma A, Arora P, Sharma A, Tyagi A. An updated review on Antihyperlipidemic Medicinal Plants. International Journal of Pharmaceutical Research and Applications. 7:1024. doi:10.35629/7781-070510241029

Understanding Hyperlipidemia: A Comprehensive Guide. 2025.

P Mumthaj, P Natarajan, A.M Janani, J Vijay, V Gokul. A Global Review Article on Hyperlipidemia. Int J Pharm Sci Rev Res. 2021 May 15;68(1). doi:10.47583/ijpsrr.2021.v68i01.018

Shattat GF. A review article on hyperlipidemia: Types, treatments and new drug targets. Biomedical and Pharmacology Journal. Oriental Scientific Publishing Company; 2014. p. 399–409. doi:10.13005/bpj/504

Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004;6(2):148–57. doi:10.1007/s11883-004-0104-8 PubMed PMID: 15023300.

Walke PP, Lahoti SR, Educational Trust B AY, Zakeria Marg R. Sulfobutyl Ether Β-Cyclodextrine (Sbe-Β-Cd): A Breakthrough for Solubility Enhancement. Walke et al World Journal of Pharmaceutical Research 2162 World Journal of Pharmaceutical Research SJIF Impact Factor 8. 2024; 13(11):2163. doi:10.20959/wjpr202411-32730

Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine. 2011 Jan 20; 364(3):226–35. doi:10.1056/nejmoa1002358 Pub Med PMID: 21247313.

Gibson Mark JB. Pharmaceutical dosage forms: Parenteral medications Volume 2. In: Gibson M, editor. Pharmaceutical Preformulation and Formulation. 2 nd. New York, London: Informa Healthcare; 2004. p. 330–1.

Desai RC, Metzger E, Santini C, Meinke PT, Heck J V., Berger JP, et al. Design and synthesis of potent and subtype-selective PPARα agonists. Bioorg Med Chem Lett. 2006 Mar 15; 16(6):1673–8. doi:10.1016/j.bmcl.2005.12.022 Pub Med PMID: 16384704.

Miyachi H, Nomura M, Tanase T, Takahashi Y, Ide T, Tsunoda M, et al. Design, Synthesis and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Peroxisome Proliferator-Activated Receptor (PPAR) Activators: Novel Human PPAR-Selective Activators.

Banker-Rhodes. Modern Pharmaceutics. 4th ed. Marcel Dekker, Inc; 2004. 501–573 p.

Shakya AK, Al-Najjar BO, Deb PK, Naik RR, Tekade RK. First-Pass Metabolism Considerations in Pharmaceutical Product Development. In: Dosage Form Design Considerations: Volume I. Elsevier; 2018. p. 259–86. doi

Downloads

Published

2026-04-15

How to Cite

Rutuja Talekar, Nanasaheb Gorade, Sachin Jadhav, Pratiksha Chormage, Shivani Gadekar, Swati H.Tarkase, & Dr.Gajanan Sanap. (2026). An Antihyperlipidemic Agents Review for Atherosclerosis Treatment . Asian Journal of Pharmaceutical Research and Development, 14(2), 174–181. https://doi.org/10.22270/ajprd.v14i2.1734

Issue

Vol. 14 No. 2 (2026): Volume 14 Issue 2 March- April. 2026

Section

Review Articles

License

Copyright (c) 2026 Rutuja Talekar, Nanasaheb Gorade, Sachin Jadhav, Pratiksha Chormage, Shivani Gadekar, Swati H.Tarkase, Dr.Gajanan Sanap

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).